Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

B2B sales

- PMLiVE

Imbruvica and Gazyvo approved in first non-chemo CLL use

Further boost for blockbuster leukaemia drug

- PMLiVE

Hardy returns to Genentech as CEO

In other news, Vertex fires chief operating officer

- PMLiVE

Morphosys’ Darzalex patent challenge hits a hurdle

Genmab and J&J's myeloma drug is a blockbuster

20 ways to improve your pharma exhibition stands

20 ways to improve your pharma exhibition stands

Healthcare and pharmaceutical companies invest a lot of money to attend exhibitions, so it’s vital that this investment pays off. However, all too often these organisations come to tradeshows with...

Apex Events and Exhibitions

Pharma Stand Project Management

What are the benefits of pharma exhibition stand project management?

You know that exhibition stands are a fantastic way to get noticed and promote your healthcare or pharmaceutical business to a captive and targeted audience. But are you making the...

Apex Events and Exhibitions

- PMLiVE

European Medicines Agency departs London ahead of Brexit

Regulator moving to Amsterdam, as Novartis adds voice to no-deal warnings

Whenever, wherever – the new face of flexible working

Flexible, agile, dynamic or smart working is now one of the key differentiators for agency employers

What does the new NHS plan mean for pharma?

Steve How and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of the NHS Long-term Plan

Wilmington Healthcare

- PMLiVE

European biosimilars hit AbbVie’s Humira revenues in Q4

Strong full year growth, but M&A speculation will linger

- PMLiVE

Ministerial revolt looming over ‘no-deal’ Brexit risk

Airbus CEO says no-deal Brexit could force it to relocate

Bristol Myers Squibb logo

BMS isn’t phased by Opdivo’s slowing growth – for now

Lung cancer filing withdrawn after FDA reservations

Credit Score

Asking patients to prove they can pay for healthcare is inhumane. Period.

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links